The second trial evaluates oncolytic MG1-MAGEA3 with Ad-MAGEA3 in combination with pembrolizumab (anti-PD-1 antibody) for previously treated metastatic non-small cell lung cancer. This evidence concerns the gene MAGEA3 and non-small cell lung carcinoma.